This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stock Market News for Oct 14, 2020
by Zacks Equity Research
Wall Street closed lower on Tuesday due to uncertainty on second round of coronavirus-aid package.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
5 Must-Buy Blue Chip Stocks to Remain Safe in October
by Nalak Das
It will be prudent to invest in Dow stocks with a favorable Zacks Rank that are likely to provide solid returns in the near term.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $154.49, marking a -1.52% move from the previous day.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), JPMorgan Chase (JPM) and Eli Lilly (LLY).
Company News for Oct 8, 2020
by Zacks Equity Research
Companies in the news are: LLY, SUNW, SOL, KIN
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
Best COVID Drug Stocks to Buy on Trump Recovery
by David Bartosiak
Two of the best COVID drug stocks to buy became evident following President Trump's speedy recovery.
Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.
4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings
by Sweta Killa
We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.
Current Outlook Gloomy
by Zacks Equity Research
Current Outlook Gloomy
A Murky Way Forward, Plus Lilly's New Candidate
by Mark Vickery
There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
by Zacks Equity Research
DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $146.63, marking a +0.98% move from the previous day.
Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive
by Zacks Equity Research
The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.
Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance
by Zacks Equity Research
The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.
Why Lilly (LLY) Could Beat Earnings Estimates Again
by Zacks Equity Research
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.